Samsung Biologics Co., Ltd.
207940 · Korea Exchange (KRX) — KOSPI · Healthcare — Biopharmaceutical Manufacturing (CDMO)
公司简介
Samsung Biologics is the world's largest contract development and manufacturing organization (CDMO) by biopharmaceutical production capacity, producing biologics drugs for pharmaceutical clients across four large-scale plants in Incheon, South Korea. The company is a Samsung Group affiliate and is constructing a fifth plant to further expand capacity. It serves leading global pharmaceutical companies and benefits from growing biologic drug outsourcing trends.
| 交易所 | Korea Exchange (KRX) — KOSPI |
| 股票代码 | 207940 |
| 行业 | Healthcare — Biopharmaceutical Manufacturing (CDMO) |
| 参考市值 美元 | $54.00B |
| 网站 | 访问官网 |
实时报价
正在加载实时价格……
| 市值 | |
| 当日区间 | |
| 52周区间 |
购买渠道
在其本地市场（Korea Exchange (KRX) — KOSPI），可通过以下提供该交易所准入的全球券商进行投资：
- Interactive Brokers — Direct access to 90+ markets worldwide, including many emerging exchanges.
- Saxo Bank — Multi-market access across Asia, Europe and the Middle East.
- Charles Schwab (Global) — Foreign ordinary shares on select markets; US-listed ADRs and ETFs.
- Fidelity International Trading — International stock trading on a number of developed and emerging markets.
- Korea Exchange — 官方交易所上市信息
仅为准入信息参考，不构成推荐或购买要约。请向您的券商确认资格、费用及当前可用性。
South Korea的其他公司
公司数据及任何实时价格均为参考性质，可能存在延迟或不准确，仅供研究参考，不构成投资建议。请以交易所、公司公告及您的券商信息为准。